Cargando…
Efficacy and safety of liposome-paclitaxel/liposome-paclitaxel combined with S-1 in 17 advanced gastric cancer patients with poor performance status
BACKGROUND: To evaluate the efficacy and safety of liposome-paclitaxel (L-PTX)/L-PTX plus S-1 in advanced gastric cancer patients with poor performance status (PS). METHODS: We performed this retrospective study on 17 advanced gastric cancer patients with poor PS [rated as ≥2 based on the Eastern Co...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798635/ https://www.ncbi.nlm.nih.gov/pubmed/35116918 http://dx.doi.org/10.21037/tcr.2019.08.17 |
_version_ | 1784641856028540928 |
---|---|
author | Wu, Runhong Shen, Zhu Yu, Na Xu, Jianhao Yuan, Xuya Ni, Liwei Long, Yuming Tao, Jialong Zhang, Yusong |
author_facet | Wu, Runhong Shen, Zhu Yu, Na Xu, Jianhao Yuan, Xuya Ni, Liwei Long, Yuming Tao, Jialong Zhang, Yusong |
author_sort | Wu, Runhong |
collection | PubMed |
description | BACKGROUND: To evaluate the efficacy and safety of liposome-paclitaxel (L-PTX)/L-PTX plus S-1 in advanced gastric cancer patients with poor performance status (PS). METHODS: We performed this retrospective study on 17 advanced gastric cancer patients with poor PS [rated as ≥2 based on the Eastern Cooperative Oncology Group (ECOG) scale] who underwent the following chemotherapy regimen: (I) L-PTX single-agent: L-PTX 60–80 mg/m(2) given on days 1 and 8, in a 21-day cycle; (II) timed sequential (TS) regimen: L-PTX 60–80 mg/m(2) given on days 1 and 8. S-1, 40–60 mg/m(2) twice a day on days 1–14, in a 21-day cycle. Initially, some patients could not tolerate the 2-drug combination chemotherapy regimen, only L-PTX single-agent was given. After the patient’s physical condition was improved, plus S-1 was also given. RESULTS: A total of 17 patients were studied. No complete response (CR) or partial response (PR) were observed in six patients, accounting for 35.29% (6/17). Stable disease (SD) was observed in five patients, accounting for 29.41% (5/17), and progressive disease (PD) in 6, accounting for 35.29% (6/17). The objective response and disease control rates were 35.29% (6/17) and 64.71% (11/17), respectively. The median progression-free survival (PFS) and median overall survival (OS) were 6.50 months [95% confidence interval (CI): 4.81–8.20] and 13.00 months (95% CI: 0.00–33.65), respectively. The most common hematological toxicities were neutropenia and anemia. CONCLUSIONS: L-PTX/L-PTX plus S-1 in the treatment of advanced gastric cancer patients with poor PS can prolong the patients’ PFS and OS, and the toxicity is tolerable. |
format | Online Article Text |
id | pubmed-8798635 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-87986352022-02-02 Efficacy and safety of liposome-paclitaxel/liposome-paclitaxel combined with S-1 in 17 advanced gastric cancer patients with poor performance status Wu, Runhong Shen, Zhu Yu, Na Xu, Jianhao Yuan, Xuya Ni, Liwei Long, Yuming Tao, Jialong Zhang, Yusong Transl Cancer Res Original Article BACKGROUND: To evaluate the efficacy and safety of liposome-paclitaxel (L-PTX)/L-PTX plus S-1 in advanced gastric cancer patients with poor performance status (PS). METHODS: We performed this retrospective study on 17 advanced gastric cancer patients with poor PS [rated as ≥2 based on the Eastern Cooperative Oncology Group (ECOG) scale] who underwent the following chemotherapy regimen: (I) L-PTX single-agent: L-PTX 60–80 mg/m(2) given on days 1 and 8, in a 21-day cycle; (II) timed sequential (TS) regimen: L-PTX 60–80 mg/m(2) given on days 1 and 8. S-1, 40–60 mg/m(2) twice a day on days 1–14, in a 21-day cycle. Initially, some patients could not tolerate the 2-drug combination chemotherapy regimen, only L-PTX single-agent was given. After the patient’s physical condition was improved, plus S-1 was also given. RESULTS: A total of 17 patients were studied. No complete response (CR) or partial response (PR) were observed in six patients, accounting for 35.29% (6/17). Stable disease (SD) was observed in five patients, accounting for 29.41% (5/17), and progressive disease (PD) in 6, accounting for 35.29% (6/17). The objective response and disease control rates were 35.29% (6/17) and 64.71% (11/17), respectively. The median progression-free survival (PFS) and median overall survival (OS) were 6.50 months [95% confidence interval (CI): 4.81–8.20] and 13.00 months (95% CI: 0.00–33.65), respectively. The most common hematological toxicities were neutropenia and anemia. CONCLUSIONS: L-PTX/L-PTX plus S-1 in the treatment of advanced gastric cancer patients with poor PS can prolong the patients’ PFS and OS, and the toxicity is tolerable. AME Publishing Company 2019-09 /pmc/articles/PMC8798635/ /pubmed/35116918 http://dx.doi.org/10.21037/tcr.2019.08.17 Text en 2019 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
spellingShingle | Original Article Wu, Runhong Shen, Zhu Yu, Na Xu, Jianhao Yuan, Xuya Ni, Liwei Long, Yuming Tao, Jialong Zhang, Yusong Efficacy and safety of liposome-paclitaxel/liposome-paclitaxel combined with S-1 in 17 advanced gastric cancer patients with poor performance status |
title | Efficacy and safety of liposome-paclitaxel/liposome-paclitaxel combined with S-1 in 17 advanced gastric cancer patients with poor performance status |
title_full | Efficacy and safety of liposome-paclitaxel/liposome-paclitaxel combined with S-1 in 17 advanced gastric cancer patients with poor performance status |
title_fullStr | Efficacy and safety of liposome-paclitaxel/liposome-paclitaxel combined with S-1 in 17 advanced gastric cancer patients with poor performance status |
title_full_unstemmed | Efficacy and safety of liposome-paclitaxel/liposome-paclitaxel combined with S-1 in 17 advanced gastric cancer patients with poor performance status |
title_short | Efficacy and safety of liposome-paclitaxel/liposome-paclitaxel combined with S-1 in 17 advanced gastric cancer patients with poor performance status |
title_sort | efficacy and safety of liposome-paclitaxel/liposome-paclitaxel combined with s-1 in 17 advanced gastric cancer patients with poor performance status |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798635/ https://www.ncbi.nlm.nih.gov/pubmed/35116918 http://dx.doi.org/10.21037/tcr.2019.08.17 |
work_keys_str_mv | AT wurunhong efficacyandsafetyofliposomepaclitaxelliposomepaclitaxelcombinedwiths1in17advancedgastriccancerpatientswithpoorperformancestatus AT shenzhu efficacyandsafetyofliposomepaclitaxelliposomepaclitaxelcombinedwiths1in17advancedgastriccancerpatientswithpoorperformancestatus AT yuna efficacyandsafetyofliposomepaclitaxelliposomepaclitaxelcombinedwiths1in17advancedgastriccancerpatientswithpoorperformancestatus AT xujianhao efficacyandsafetyofliposomepaclitaxelliposomepaclitaxelcombinedwiths1in17advancedgastriccancerpatientswithpoorperformancestatus AT yuanxuya efficacyandsafetyofliposomepaclitaxelliposomepaclitaxelcombinedwiths1in17advancedgastriccancerpatientswithpoorperformancestatus AT niliwei efficacyandsafetyofliposomepaclitaxelliposomepaclitaxelcombinedwiths1in17advancedgastriccancerpatientswithpoorperformancestatus AT longyuming efficacyandsafetyofliposomepaclitaxelliposomepaclitaxelcombinedwiths1in17advancedgastriccancerpatientswithpoorperformancestatus AT taojialong efficacyandsafetyofliposomepaclitaxelliposomepaclitaxelcombinedwiths1in17advancedgastriccancerpatientswithpoorperformancestatus AT zhangyusong efficacyandsafetyofliposomepaclitaxelliposomepaclitaxelcombinedwiths1in17advancedgastriccancerpatientswithpoorperformancestatus |